http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02094198-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc2b03342511abc88f60c63f2acd96d0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-463 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-46 |
| filingDate | 2002-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af3ee5049d9c8f6432d11ce7c1ea9cee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a08892f2b5ee0f925e562c5200b1ef98 |
| publicationDate | 2002-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-02094198-A2 |
| titleOfInvention | Modulation of cell division by an early mitotic inhibitor protein |
| abstract | Emi1 regulates progression through early mitosis by preventing premature APC activation. Depleting Emi1 from cycling cells strongly delays cyclin B accumulation and mitotic entry, while expression of a stabilized form of Emi1 stabilizes APC substrates and causes a mitotic block. Emi1 binds the APC activators Cdc20 and Cdh1 and inhibits APC activation by Cdc20 or Cdh1. Hence, products that modulate the expression and/or activity of Emi1 have a therapeutic effect in the treatment of cancer, leukemia, solid tumors, chronic or acute inflammatory disease, restenosis, diabetes, neurological disorders, arthritis and osteoporosis, among other indications. |
| priorityDate | 2001-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 676.